title: Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. 1990.
authors.forename: S
authors.initials: S
authors.lastname: Boyce
authors.forename: N M
authors.initials: NM
authors.lastname: Rupniak
authors.forename: M J
authors.initials: MJ
authors.lastname: Steventon
authors.forename: S D
authors.initials: SD
authors.lastname: Iversen
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000009:adverse effects / Q000266:history*; D000818:Animals; D015259:Dopamine Agents / Q000009:adverse effects / Q000266:history*; D018491:Dopamine Agonists / Q000266:history* / Q000627:therapeutic use; D049673:History, 20th Century; D010300:Parkinson Disease / Q000266:history*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D017447:Receptors, Dopamine D1 / Q000819:agonists / Q000266:history*; D017448:Receptors, Dopamine D2 / Q000819:agonists / Q000266:history*; D012453:Saimiri
chemical_list: D015259:Dopamine Agents; D018491:Dopamine Agonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine